{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:01:41Z","timestamp":1781074901853,"version":"3.54.1"},"reference-count":16,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Palliative Medicine Reports"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Opioids are commonly initiated prior to dinutuximab (DIN)\u2014an anti-disialoganglioside 2 antibody used in the treatment of neuroblastoma\u2014and continued for approximately 2 hours after administration to manage DIN-associated pain. However, pain control remains insufficient with standard opioid treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We treated a 3-year-old girl with high-risk neuroblastoma who received DIN after tandem transplantation. During the first treatment cycle, despite scheduled morphine therapy, she developed abdominal pain rated as 5 on the Faces Pain Scale (FPS; range 0\u20135, where 0 indicates no pain and 5 indicates the worst pain), indicating the need for higher doses, prolonged infusion, and additional bolus analgesia. The dosing period and DIN dosage in the second cycle were similar to those in the first cycle. To improve pain control during the second cycle, pregabalin was initiated at a dose of approximately 1 mg\/kg\/day 3 days prior to DIN administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This approach significantly reduced abdominal pain, with the maximum FPS score decreasing to 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This case highlights that adding pregabalin to standard opioid therapy can contribute to improved management of DIN-induced pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/26892820261452103","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:55:33Z","timestamp":1780901733000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination Therapy with Pregabalin and Morphine Relieves Dinutuximab-Induced Pain in a 3-Year-Old Girl: A Case Report"],"prefix":"10.1177","volume":"7","author":[{"given":"Maiko","family":"Akazawa","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan."},{"name":"Pediatric Palliative Care Team, Kyoto University Hospital, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-5357","authenticated-orcid":false,"given":"Yuki","family":"Shigetsura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Kawakatsu","sequence":"additional","affiliation":[{"name":"Pediatric Palliative Care Team, Kyoto University Hospital, Kyoto, Japan."},{"name":"Department of Nursing, Kyoto University Hospital, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Pediatric Palliative Care Team, Kyoto University Hospital, Kyoto, Japan."},{"name":"Department of Nursing, Kyoto University Hospital, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kubota","sequence":"additional","affiliation":[{"name":"Pediatric Palliative Care Team, Kyoto University Hospital, Kyoto, Japan."},{"name":"Department of Pediatrics, Kyoto University Hospital, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7735-3918","authenticated-orcid":false,"given":"Kazuki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Pediatric Palliative Care Team, Kyoto University Hospital, Kyoto, Japan."},{"name":"Department of Palliative Medicine, Kyoto University Hospital, Kyoto, Japan."},{"name":"School of Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"issue":"4","key":"e_1_3_2_2_1","first-page":"1098","article-title":"Disialoganglioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth","volume":"47","author":"Mujoo K","year":"1987","unstructured":"1.Mujoo K, , Cheresh DA, , Yang HM, et al. Disialoganglioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987;47(4):1098\u20131104.","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_3_2_3_1","first-page":"144","article-title":"Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells","volume":"51","author":"Barker E","year":"1991","unstructured":"2.Barker E, , Mueller BM, , Handgretinger R, et al. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991;51(1):144\u2013149.","journal-title":"Cancer Res"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312648"},{"key":"e_1_3_2_5_1","unstructured":"4.Ohara Pharmaceutical Co. Ltd. Phase 2b study of combined immunotherapy with dinutuximab interleukin-2 and G-CSF for high risk neuroblastoma. Pharmaceuticals and Medical Devices Agency: Tokyo; 2021. Available from: https:\/\/www.pmda.go.jp\/drugs\/2021\/P20210702002\/180095000_30300AMX00291_K107_1.pdf [Last accessed: November1 2025]."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3779"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123"},{"key":"e_1_3_2_8_1","first-page":"469","volume-title":"Nelson Textbook of Pediatrics","author":"Zeltzer LK","year":"2020","unstructured":"7.Zeltzer LK, , Krane EJ, , Levy RLPediatric pain management. In: Kliegman RM, , St Geme JW, , Blum NJ, et al. (eds) Nelson Textbook of Pediatrics. Elsevier: Amsterdam; 2020, pp. 469\u2013490, 3104t-5t."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30217"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25280"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134255"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S487724"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199801000-00022"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1907805"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1668"},{"key":"e_1_3_2_16_1","unstructured":"15.Pharmaceuticals and Medical Devices Agency. Review report: Lyrica (Pregabalin). 2013. Available from: https:\/\/www.pmda.go.jp\/drugs\/2013\/P201300010\/671450000_22200AMX00297_A100_3.pdf [Last accessed: December24 2025]."},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2013.628"}],"container-title":["Palliative Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26892820261452103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/26892820261452103","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26892820261452103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:46:13Z","timestamp":1781073973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/26892820261452103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":16,"alternative-id":["10.1177\/26892820261452103"],"URL":"https:\/\/doi.org\/10.1177\/26892820261452103","relation":{},"ISSN":["2689-2820","2689-2820"],"issn-type":[{"value":"2689-2820","type":"print"},{"value":"2689-2820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"26892820261452103"}}